Pressmeddelande

BioStock: Q2 marked continued progress for Medivir in advanced liver cancer

Cision Publicerad: 26 Aug 09:50

At the ESMO GI congress in June, Medivir presented greatly improved results for patients with advanced liver cancer in the ongoing phase Ib/IIa study with fostrox in combination with Lenvima. The company is increasingly optimistic about the possibility of launching the first approved drug treatment after first-line treatment of the disease. This is evident from Medivir’s interim report.
– We are now looking forward to presenting detailed and mature clinical data from the study with fostrox at the ESMO Cancer Congress in Barcelona in September, says CEO Jens Lindberg.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/08/q2-marked-continued-progress-for-medivir-in-advanced-liver-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Nyheter om Medivir

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!